(Lung Cancer) Is Aumolertinib Effective?
(Lung Cancer) Is Aumolertinib Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
(Lung Cancer) Is Aumolertinib Effective?
- June 1, 2022
- 1 min read
On May 17, 2022, Shun Lu et al. from Shanghai Chest Hospital published in the medical journal Journal of Clinical Oncology the efficacy and safety results of Aumolertinib monotherapy as first-line treatment for advanced, metastatic non-small cell lung cancer patients with EGFR mutations (Exon 19 deletion and Exon L858R mutation) in the AENEAS Phase III clinical trial.
AENEAS was a double-blind Phase III clinical trial that randomized advanced, metastatic non-small cell lung cancer patients with EGFR mutations (Exon 19 deletion and Exon L858R mutation) (N=429) into the Aumolertinib group (once daily, 110 mg) and the Gefitinib group (once daily, 250 mg). The primary endpoint was progression-free survival.
The trial results showed that the primary endpoint median progression-free survival was 19.3 months for the Aumolertinib group and 9.9 months for the Gefitinib group. Compared to the Gefitinib group, the Aumolertinib group showed a 54% reduction in death risk (progression-free survival).
Secondary endpoint objective response rates were 73.8% for the Aumolertinib group and 72.1% for the Gefitinib group. Disease control rates were 93.0% for the Aumolertinib group and 96.7% for the Gefitinib group. Median duration of response was 18.1 months for the Aumolertinib group and 8.3 months for the Gefitinib group.
Regarding safety, grade 3 or higher adverse event rates were 36.4% for the Aumolertinib group and 35.8% for the Gefitinib group. Skin-related adverse event rates were 23.4% for the Aumolertinib group and 41.4% for the Gefitinib group. Diarrhea rates were 16.4% for the Aumolertinib group and 35.8% for the Gefitinib group.
Based on the AENEAS trial results, Shun Lu et al. stated that Aumolertinib monotherapy as first-line treatment for advanced, metastatic non-small cell lung cancer patients with EGFR mutations (Exon 19 deletion and Exon L858R mutation) shows promise as a new treatment option for these patients.
Source: https://ascopubs.org/doi/full/10.1200/JCO.21.02641
-
Investigational Drugs
(Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Results in Phase II Clinical Trial. (Lung Cancer) Is Trastuzumab deruxtecan Effective for HER2-Mutant Non-Small Cell Lung Cancer? (Lung Cancer) Is the Anti-B7-H3 Antibody Drug DS-7300 Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.